Identification of a thromboplastin inhibitor in serum and in plasma.
Identification of a thromboplastin inhibitor in serum and in plasma.
复制标题
血清和血浆中凝血活酶抑制剂的鉴定。
DOI：
--
复制
发表时间：
1953
影响因子：
15.9
通讯作者：
A. G. Ware
中科院分区：
文献类型：
--
作者：
G. F. Lanchantin;A. G. Ware
直到最近，血液中的凝血活酶抑制剂还很少受到关注。 Tocantins 在过去十年中提供的证据支持正常血浆中存在凝血活酶抑制剂的观点 (1, 2)。他的工作最终从正常人血浆中分离出一种脂质抑制剂，他将其命名为“抗脑磷脂”(3)。该因子是一种强烈的凝血抑制剂，显然起到凝血活酶拮抗剂的作用。它作为血浆中甲醇可溶性、乙醚可溶性部分被分离出来，并以比正常人活性数倍的形式从血友病患者中获得。 Tocantins 最近的观察结果使这一基本信息变得更加有趣，即血友病血浆优球蛋白在适当稀释后可以促进整个血友病血浆的凝血 (4)。 Overman 和 Wright 描述了一种从血浆、组织和大豆中分离出来的肌醇磷脂 (5, 6)。这种脂质是一种凝血抑制剂，被认为以涉及凝血活酶的复杂方式发挥作用。该抑制剂的制备方法尚未公布，但推测该过程与 Tocantins (3) 描述的过程类似。 Fiala 描述了一种凝血蛋白抑制剂，它通过碳酸钡、硫酸钡和硅藻土从草酸血浆中吸附 (7, 8)。没有描述该抑制剂的作用方式。作为血清中凝血活酶抑制剂的指示，更令人印象深刻的是 Schneider (9) 和 Thomas (10) 的工作。这些研究人员独立证明人血清可以有效灭活组织凝血活酶。两者都使用了体内测定技术
Thromboplastin inhibitors in the blood have received little attention until recently. Tocantins has presented evidence during the past decade which supports the view that a thromboplastin inhibitor exists in normal plasma (1, 2). His work has culminated in the isolation of a lipid inhibitor from normal human plasma which he named "anticephalin" (3). This factor is a strong inhibitor of clotting apparently acting as a thromboplastin antagonist. It is isolated as the methyl alcoholsoluble, ether-soluble fraction of plasma and is obtained from the hemophiliac in a form several times more active than normal. This fundamental information is made even more interesting by Tocantins' recent observations that hemophilic plasma euglobulins, after proper dilution, can promote clotting in whole hemophilic plasma (4). Overman and Wright described an inositol phosphatide which was separated from plasma as well as from tissues and from soy beans (5, 6). This lipid is an inhibitor of clotting which was thought to act in a complex manner involving thromboplastin. A method of preparation of the inhibitor was not published but it is assumed that the procedure was similar to that described by Tocantins (3). Fiala has described a protein inhibitor of clotting which is adsorbed from oxalated plasma by barium carbonate, barium sulfate and celite (7, 8). The manner of action of this inhibitor was not described. Much more impressive as an indication of a thromboplastin inhibitor in serum is the work of Schneider (9) and of Thomas (10). These investigators demonstrated independently that human serum can effectively inactivate tissue thromboplastin. Both used an in uivo assay technic for